Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:BCDA NASDAQ:ELAB NASDAQ:GOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.32+18.5%$0.22$0.15▼$13.00$16.17MN/A12.50 million shs61.20 million shsBCDABioCardia$2.35+1.7%$2.18$1.63▼$4.66$12.71M0.81236,529 shs30,852 shsELABPMGC$2.28-1.3%$2.26$1.95▼$660.80$3.18M0.13177,550 shs53,791 shsGOVXGeoVax Labs$0.79-2.8%$0.89$0.43▼$11.18$12.94M3.362.78 million shs1.37 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-8.96%+35.63%+24.93%-16.32%+26,609,900.00%BCDABioCardia-3.75%+1.32%+5.96%+17.26%-18.66%ELABPMGC0.00%+0.87%+5.96%+2.21%-99.63%GOVXGeoVax Labs-4.51%+11.21%-9.92%-16.82%-68.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia3.4971 of 5 stars3.83.00.00.03.82.50.6ELABPMGC0.4772 of 5 stars0.04.00.00.01.50.00.6GOVXGeoVax Labs1.8955 of 5 stars3.52.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,168.23% UpsideBCDABioCardia 3.50Strong Buy$25.00963.83% UpsideELABPMGC 0.00N/AN/AN/AGOVXGeoVax Labs 3.00Buy$8.881,023.42% UpsideCurrent Analyst Ratings BreakdownLatest ELAB, ABP, BCDA, and GOVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K106.52N/AN/A($0.29) per share-1.09BCDABioCardia$60K215.42N/AN/A$0.18 per share13.06ELABPMGC$1.71M1.84N/AN/A$11.53 per share0.20GOVXGeoVax Labs$5.59M2.25N/AN/A$0.48 per share1.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/ABCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)ELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)GOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%7/28/2025 (Estimated)Latest ELAB, ABP, BCDA, and GOVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/28/2025Q2 2025GOVXGeoVax Labs-$0.41N/AN/AN/A$0.37 millionN/A5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11BCDABioCardiaN/A0.360.36ELABPMGCN/A8.978.97GOVXGeoVax LabsN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%BCDABioCardia20.57%ELABPMGC22.22%GOVXGeoVax Labs6.09%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%BCDABioCardia20.00%ELABPMGC0.60%GOVXGeoVax Labs1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/ABCDABioCardia405.50 million4.40 millionOptionableELABPMGC181.38 million1.37 millionN/AGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableELAB, ABP, BCDA, and GOVX HeadlinesRecent News About These CompaniesCritical Comparison: GeoVax Labs (NASDAQ:GOVX) versus KALA BIO (NASDAQ:KALA)July 25 at 4:07 AM | americanbankingnews.comWall Street Zen Downgrades GeoVax Labs (NASDAQ:GOVX) to SellJuly 22 at 3:25 AM | americanbankingnews.comGeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox VaccineJuly 21, 2025 | finance.yahoo.comGeoVax Labs Inc. (NASDAQ:GOVX) Given Average Recommendation of "Buy" by AnalystsJuly 19, 2025 | americanbankingnews.comGeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks ExpandJuly 16, 2025 | finance.yahoo.comGeoVax Labs (NASDAQ:GOVX) Upgraded by Wall Street Zen to "Hold" RatingJuly 15, 2025 | americanbankingnews.comGeoVax Labs, Inc. (GOVX) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comGeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health ThreatJuly 3, 2025 | finance.yahoo.comGeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense ObjectivesJuly 2, 2025 | finance.yahoo.comGOVX - Geovax Labs Inc Dividends - MorningstarJuly 2, 2025 | morningstar.comMEQS-News: GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public OfferingJuly 1, 2025 | finanzen.atFGeoVax to Raise Approximately $6 Million of Gross Proceeds in Public OfferingJuly 1, 2025 | finance.yahoo.comGeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - NasdaqJune 27, 2025 | nasdaq.comGeoVax Comments on FDA Approval of Keytruda (R) in Head and Neck Cancer, Underscoring Potential for Gedeptin (R) Combination Therapy - NasdaqJune 26, 2025 | nasdaq.comGeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria InfectionJune 25, 2025 | theglobeandmail.comEQS-News: GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination TherapyJune 24, 2025 | finanzen.atFGeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination TherapyJune 24, 2025 | finance.yahoo.comGeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 MeetingJune 17, 2025 | finance.yahoo.comGeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVAJune 16, 2025 | finance.yahoo.comGeoVax to Participate in BIO International Convention 2025June 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, ABP, BCDA, and GOVX Company DescriptionsAbpro NASDAQ:ABP$0.32 +0.05 (+18.53%) As of 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.BioCardia NASDAQ:BCDA$2.35 +0.04 (+1.73%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.02 (+0.64%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.PMGC NASDAQ:ELAB$2.28 -0.03 (-1.30%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.06 (+2.68%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.GeoVax Labs NASDAQ:GOVX$0.79 -0.02 (-2.77%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
